#NEWS: New data at #AAAAI25 reinforce our scientific leadership and commitment to innovation across immune-meditated diseases, including #CSU, #asthma and #COPD. Read about our presentations ⤵️ CC: @Regeneron

#NEWS: China’s National Medical Products Administration has approved our combination therapy for adult patients with newly diagnosed #MultipleMyeloma ineligible for transplant. Learn more ⬇️

Our CEO, Paul Hudson, reflects on the pivotal role innovation plays in driving our growth. Learn more: #SanofiResults $SAN $SNY

Our Q4 & Full-Year 2024 results are now available. Learn more. ⤵️ #SanofiResults $SAN $SNY

#NEWS: @EU_Commission has approved our combination therapy for adult patients with newly diagnosed #MultipleMyeloma ineligible for transplant in the EU. Learn more ⬇️

The biopharma industry is entering a transformative era. In an article with the @wef, our CEO Paul Hudson discusses four key areas that can power the progress of medicine 2025. Read more 👇 #WEF25 #WorldEconomicForum #Biopharma

Our commitment to excellence in R&D combines our deep understanding of the immune system with patient-informed insights and #AI. Learn how we’re driving the discovery of tomorrow’s medicines to improve lives around the world.

#NEWS: China’s National Medical Products Administration has approved our combination therapy for adult patients with relapsed or refractory #MultipleMyeloma. Learn more ⬇️

#NEWS: Latest phase 3 study evaluating our investigational subcutaneous #MultipleMyeloma combination therapy met key endpoints in relapsed or refractory patients. Learn more ⬇️

Here’s to health, progress and achievements in 2025. Let’s make the new year amazing – together! 🧬 #HappyNewYear #2025 #WeNeverSettle

#NEWS: We launched the phase 3 clinical program for our 21-valent #pneumococcal conjugate vaccine candidate and expanded our partnership with SK bioscience to develop next-generation vaccines. Together, we’re pushing boundaries to help protect more lives. Learn more ⬇️

#NEWS: The @US_FDA granted Breakthrough Therapy designation to our investigational treatment for non-relapsing secondary progressive #MultipleSclerosis, an area of unmet need for the community. Read our press release ➡️

#NEWS: Today the @US_FDA granted Fast Track designation for our two combination vaccine candidates to prevent #influenza and #COVID19 infections. Learn More ⬇️

#NEWS: At #ASH24, we shared pivotal data about our investigational treatment for #ImmuneThrombocytopenia (ITP), and new phase 3 data evaluating our combination regimens in newly diagnosed #MultipleMyeloma.

How are we ensuring transparency in #AI? 🧠 We prioritize transparency in AI systems with risk assessments, guidelines, and training to ensure reliable outputs. Our approved AI tools support our Digital R&D team in analyzing #clinicaltrial data to predict patient risk factors.

Last week, we hosted our first global Hackathon on AI agents with 250 top users from France, USA and China. 💡 They designed AI Agents to revolutionize decision intelligence across our organization. Over 31,000 Sanofians upskilled in AI through a masterclass and quizzes.

@Ferd14k9Ferd Hi @Ferd14k9Ferd, we’re unable to discuss products on social media but you can send us your questions via the contact form on our website: If you have questions or concerns about your health, please talk to your healthcare provider.

Proud to be #3 in the 2024 Access to Medicine Index This reflects our access planning efforts and the impact of our GHU in improving product access in LMICs, building partnerships, and driving an inclusive business model recognized as a “Best Practice” by the @AtMIndex #ATMI24

#NEWS: The resubmission of our application for an investigational medicine for chronic spontaneous urticaria (#CSU) has been accepted for review by the @US_FDA. Learn more ⬇️ @Regeneron

#NEWS: The @EMA_News CHMP recommended the approval of our combination therapy, making strides towards a potential new treatment option for people in the EU with newly diagnosed #MultipleMyeloma who are transplant-ineligible. Learn more ⬇️